ERBB2 and breast cancer: This study retrospectively analyzed 587 medical records of Polish breast cancer patients, with a specific focus on the hormone receptor-positive, HER2-negative (HR+ HER-) subtype, to assess critical aspects of care, including waiting times, treatment coordination, cancer characteristics, diagnostic testing, and staging.